LYEL Profile
Lyell Immunopharma, Inc., a leader in T cell reprogramming technology, focuses on developing innovative T cell therapies to treat patients with solid tumors. The company's core approach involves leveraging advanced technology platforms, including Gen-R and Epi-R, to enhance the efficacy and longevity of T cell-based treatments. Gen-R is an ex vivo genetic reprogramming technology designed to combat T cell exhaustion, a common challenge in immunotherapy. Epi-R, on the other hand, employs ex vivo epigenetic reprogramming to produce T cells with lasting stemness, enhancing their ability to persist and function effectively within the tumor microenvironment.
Lyell's therapeutic pipeline includes several promising candidates. LYL797, a leading product, is under development for treating non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Another notable candidate, LYL845, targets a range of solid tumors with its broad-spectrum efficacy. Additionally, the company is advancing the NY-ESO-1 program, which focuses on synovial sarcoma and other solid tumor indications. This program is supported by a research and development collaboration with GlaxoSmithKline, aimed at accelerating the clinical development of NY-ESO-1.
Lyell Immunopharma’s approach to T cell therapy is distinguished by its emphasis on overcoming the limitations of traditional cancer immunotherapies. By addressing challenges such as T cell exhaustion and enhancing T cell persistence, Lyell aims to provide more effective and durable treatment options for patients with solid tumors. The company’s commitment to advancing these therapies reflects a broader strategy to push the boundaries of what is possible in cancer treatment through cutting-edge research and innovative technologies.
Founded in 2018 and headquartered in South San Francisco, California, Lyell Immunopharma is at the forefront of transforming cancer immunotherapy. The company's ongoing research and collaborations underscore its dedication to pioneering new solutions in oncology, with a vision to improve patient outcomes and make a significant impact in the field of cancer treatment.
|
